Critical CD12 trial Nader notes “quite a bit of
Post# of 148170
(Total Views: 814)
Posted On: 07/01/2020 12:56:21 PM
Critical CD12 trial Nader notes “quite a bit of deaths, but the data is blinded”. Given the safety profile of Leronlimab, and knowing the MOA, the odds are the majority of those deaths were in the placebo group. From that point, Nader goes to the distribution agreement.....
(1)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼